• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave i

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2026 Mar 11;13(3):ofag131.
doi: 10.1093/ofid/ofag131. eCollection 2026 Mar.
Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave in Taiwan: A National Retrospective Study

Pei-Jiuan Chao[SUP] 1 [/SUP], Wan-Chin Chen[SUP] 2 [/SUP], Angela Song-En Huang[SUP] 1 [/SUP], Chia-Ping Su[SUP] 3 4 [/SUP]


Affiliations
Abstract

Background: During Taiwan's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron outbreak in 2022, pediatric coronavirus disease 2019 (COVID-19) encephalitis cases surged, resulting in multiple fatalities. We investigated patient characteristics and mortality risk factors.
Method: Using the Brighton Collaboration criteria, we identified 289 suspected pediatric COVID-19 encephalitis cases diagnosed between April and December 2022 by linking the national surveillance, remdesivir application, immunization, and death registries. We analyzed clinical data and viral genotypes, then used univariate and multivariate logistic regressions to assess mortality risk factors.
Results: We identified 75 encephalitis cases: 50 (67%) were male, with a median age of 5 years (interquartile range [IQR]: 3-8 years), 45 (60%) had no comorbidities, and 23 (31%) had received at least 1 dose of the COVID-19 vaccine. The median interval from symptom onset to medical attention was <1 day (IQR: 0-1 day).Fourteen cases (19%) died after a median hospital stay of 3 days (IQR: 1-5 days). All sequenced viruses matched the circulating Omicron subvariants. In univariate analysis, age <5 years was associated with increased mortality (odds ratio [OR] & 6.05; 95% confidence interval [CI] & 1.53-24.00). Multivariate analysis showed a nonsignificant trend (adjusted OR & 3.64; 95% CI & 0.81-16.40) after adjustment for sex, comorbidities, and vaccination.
Conclusions: During the Omicron wave, the number of pediatric COVID-19 encephalitis cases progressed rapidly and mortality was high, particularly among children <5 years of age, regardless of comorbidities. We recommend COVID-19 vaccination and monitoring for signs of COVID-19 encephalitis in young children.

Keywords: COVID-19; SARS-CoV-2; encephalitis; omicron; pediatric.

 
Back
Top Bottom